eISSN 2508-3589
pISSN 2508-1926

Table. 5.

Table. 5.

Outcomes in the three study groups (patients placed under observation are included)

Group 1 (22)Group 2 (9)Group 3 (15)Total (56)p-value
Final BCVA (LogMAR)0.77±1.262.37±1.853.73±1.232.09±1.87< 0.001*
Final BCVA over 0.5 (decimal)12 (54.5)3 (15.8)0 (0.0)15 (26.8)< 0.001
Final BCVA over 0.1 (decimal)18 (81.8)6 (31.6)0 (0.0)24 (42.9)< 0.001
BCVA change (LogMAR)-0.45±1.17-1.73±1.70-3.08±1.51-1.59±1.78< 0.001*
Improved visual acuity6 (27.3)1 (5.3)0 (0.0)7 (12.5)0.039
Number of total operations1.00±0.821.68±0.822.20±1.201.55±1.0430.005*
Retinal detachment0 (0.0)5 (26.3)5 (33.3)10 (17.9)0.007
Vitreous hemorrhage0 (0.0)3 (15.8)2 (13.3)5 (8.9)0.110
Glaucoma2 (9.1)2 (10.5)3 (20.0)7 (12.5)0.602
Neovascularization of the iris0 (0.0)2 (10.5)2 (13.3)4 (7.1)0.173
Cataract3 (13.6)2 (10.5)3 (20.0)8 (14.3)0.797
Phthisis0 (0.0)3 (15.8)0 (0.0)3 (5.4)0.051
Enucleation1 (4.5)3 (15.8)4 (26.7)8 (14.3)0.186

Values are presented as mean±standard deviation or number (%).

BCVA = best-corrected visual acuity; LogMAR = the logarithm of minimal angle of resolution.

Kruskal-Wallis test;

Fisher’s exact test;

primary enucleated patient was excluded.

Korean J Ret 2019;4:23-31 https://doi.org/10.21561/jor.2019.4.1.23
© 2019 Korean J Ret